Most patients experience significant improvement within 48 weeks without stopping treatment
WaddenTHollanderPKleinSNiswenderKWooVHalePMet al
Both companies will face the same all-in monthly cost competition from compounded weekly semaglutide and tirzepatide ($80-$350 a month), and both will have to price near-parity for the convenience trade to land
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Ohman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF, EXSCEL Study Group
what works for one individual may not be appropriate for another
These results illustrate that GGCT regulates intracellular ROS levels primarily via GSH rather than energy metabolism